Le Lézard
Classified in: Health
Subject: PDT

A Connected Wearable Device To Predict Toilet Timing Officially Available in US


SAN DIEGO, July 16, 2018 /PRNewswire/ -- Triple W, the company that developed the world's first connected wearable device that can track the progression of bladder movements using non-invasive ultrasonic sensor, announced they will start taking pre-orders for their product today.

DFree

The device, called DFree (pronounced Dee-free), will help elderly and disabled people who suffer from incontinence by predicting and notifying the right timing to go to the bathroom.   As a result, they no longer have to worry about accidents and can often forgo the embarrassment of wearing diapers.  According to a report released by the CDC, more than 50 percent of elderly Americans struggle with incontinence.  Incontinence occurs when muscles controlling the bladder are too weak or too active.  There are other causes of incontinence, such as prostate problems and nerve damage.

A sensor is secured to the lower abdomen using medical tape and uses ultrasound to monitor the change in bladder size. The notification is then sent to a smartphone or tablet used by the patient or caregiver to inform them when it is necessary to go to the bathroom.

Atsushi Nakanishi, President and CEO for Triple W, comments: "Our goal is to help millions of people suffering from incontinence so that they can continue to live actively without worrying about having accidents."  DFree is currently used in over 500 senior care facilities in Japan and Europe, including trials. 

About DFree

DFree is a portable device, which can be worn all day indoors or outdoors to monitor your bladder activities.  The device communicates directly with a compatible smartphone or tablet using Bluetooth(R) technology.  DFree application that runs on the smartphone/tablet shows current status of the bladder and also provides a notification to let you know that you need to go to the bathroom soon.  DFree application can be downloaded for free from the Apple App Store (Android app will be released in September 2018).   

DFree is designed to help seniors, children (6 and older), and people with disability that feel insecure about overly active bladder or have difficulty sensing when they need to go to the bathroom. 

About Pre-order

DFree will retail for $499.99 and will be available to US customers.  Triple W is now accepting pre-orders on their site (https://www.dfreeus.biz) and offering 10% discount on all pre-orders.  Product will begin shipping in mid-August.

About Triple W

Triple W, founded by Atsushi Nakanishi in 2015, has offices in Tokyo, Paris and San Diego.  Triple W develops DFree, the world's first connected wearable device that can track the progression of bladder movements using a non-invasive ultrasonic sensor.  The device will help elderly, children and disabled people who suffer from incontinence by predicting and notifying the right timing to go to the bathroom.   The device is designed to not only help people with incontinence improve quality of life and enable independence, but to also help reduce the burden for the caregivers.

*DFree is not a medical device and is not intended to be used in the diagnosis, prevention, or treatment of diseases or conditions.

Media Contact

For further information and to discuss business opportunities, please contact:

Ty Takayanagi
Vice President of Marketing and Business Development
Triple W
Phone:  (833) DFREEUS (833-337-3387)
Email: [email protected] 
Website:  http://dfreeus.biz

DFree Logo

SOURCE Triple W


These press releases may also interest you

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...

at 08:00
Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD will serve as a panelist at the 2024 Oncology Fellows & Faculty Forum in Miami, sponsored by PrecisCa and the Community Oncology Alliance...



News published on and distributed by: